Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 61

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 61
---
 that indicate they are unlikely to be effective drugs; or •it may take greater human and financial resources to identify additional therapeutic opportunities for our drug candidates or to develop suitable potential drug candidates through internal research programs than we will possess, thereby limiting our ability to diversify and expand our drug portfolio. Because we have limited financial and managerial resources, we have chosen to focus at present on our three Lead Projects, which may ultimately prove to be unsuccessful. As a result of this focus, we may forego or delay pursuit of opportunities with other drug candidates, or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Even if we determine to pursue alternative therapeutic or diagnostic drug candidates, these other drug candidates or other potential programs may ultimately prove to be unsuccessful. In short, our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Accordingly, there can be no assurance that we will ever be able to develop suitable potential drug candidates through internal research programs. This could materially adversely affect our future growth and prospects. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. Although we obtained CTA/FDA approval to initiate clinical trials for our Lead Projects, there can be no assurance, timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who meet the trial criteria and remain in the trial until its conclusion. We may experience difficulties enrolling and retaining appropriate patients in our clinical trials for a variety of reasons, including but not limited to: •the size and nature of the patient population; •patient eligibility criteria defined in the clinical protocol; •the size of study population required for statistical analysis of the trial’s primary endpoints; •the proximity of patients to trial sites; •the design of the trial and changes to the design of the trial; •our ability to recruit clinical trial investigators with the appropriate competencies and experience; •competing clinical trials for similar therapies or other new therapeutics exist and will reduce the number and types of patients available to us; •clinicians’ and patients’ perceptions as to the potential advantages and side effects of the drug candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating; •our ability to obtain and maintain patient consents; •patients enrolled in clinical trials may not complete a clinical trial; and •the availability of approved therapies that are similar to